[SELANK] and Anxiety Regulation
Research utilizing murine models of generalized anxiety suggests that [SELANK] exhibits pronounced anxiolytic activity. In open-field and elevated plus-maze tests, subjects administered the peptide displayed reduced anxiety markers comparable to low-dose benzodiazepines (such as diazepam) but without the associated sedative or muscle-relaxant effects. The mechanism is hypothesized to be the modulation of GABA-A receptor gene expression and the stabilization of enkephalins in the blood serum.
[SELANK] and Cognitive Function
Studies focused on cognitive impairment—specifically induced by ethanol or sensory stress—indicate that [SELANK] may preserve memory traces and learning ability. In rat models, the peptide was observed to prevent the ethanol-induced accumulation of errors in active avoidance tasks. This nootropic potential is linked to the upregulation of BDNF (Brain-Derived Neurotrophic Factor) in the hippocampus, a critical protein for neuroplasticity and long-term memory formation.
[SELANK] and Inflammatory Response
Beyond its neurological effects, [SELANK] acts as an immunomodulator. Research indicates that the peptide influences the expression of genes involved in the inflammatory response, including IL-6 (Interleukin-6) and C3 (Complement component 3). In subjects exposed to social stress, the administration of [SELANK] was correlated with a normalization of cytokine levels, suggesting a potential role in mitigating stress-induced immune dysfunction.
[SELANK] and Depression (Anhedonia)
In WAG/Rij rats, a genetic model for depression and absence epilepsy, [SELANK] was observed to counteract symptoms of anhedonia (inability to feel pleasure). Subjects treated with the peptide showed restored sucrose preference and increased mobility in forced swim tests. These findings suggest that the peptide’s modulation of the dopamine and serotonin turnover rates contributes to an antidepressant-like effect in non-clinical models.